GATA-3 Expression as a Predictor of Hormone Response in Breast Cancer
- 1 May 2005
- journal article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 200 (5) , 705-710
Abstract
Expression of estrogen receptor-alpha (ERalpha) as determined by immunohistochemistry of tumor tissue is currently the most clinically useful test to predict hormone responsiveness of breast cancer. Thirty percent of ERalpha-positive breast cancers do not respond to hormonal therapy. GATA-3 is a transcription factor that is expressed in association with ERalpha and there is evidence that GATA factors influence response to estrogen. In this pilot study, we investigated whether GATA-3 expression is associated with hormone response in breast cancer. Breast cancer tissue was stained for GATA-3 expression by immunohistochemistry in ERalpha-positive cancers from 28 patients, 14 of whom were defined as hormone unresponsive (cases) and 14 of whom were age-matched controls with hormone-responsive, ERalpha-positive cancers (controls). Comparing cases and controls, there were no differences in expression of ERalpha; progesterone receptor, ErbB2; or tumor grade. Using 20% nuclear staining to characterize tumors as GATA-3 positive or GATA-3 negative, 6 of 14 (43%) cancers in the hormone-unresponsive group and none of the controls were classified as GATA-3 negative (odds ratio, 8.2; 95% confidence interval, 1.2-infinity; p = 0.031). Using different cut points to characterize GATA-3 positivity yielded very similar results, indicating a positive association between lack of GATA-3 expression and lack of response to hormonal therapy. The study suggests that analyzing ERalpha-positive breast tumors for GATA-3 using immunohistochemistry might improve prediction of hormone responsiveness. The association between GATA-3 expression and hormone response suggests that GATA-3 may play a role in mechanisms controlling response to estrogen.Keywords
This publication has 26 references indexed in Scilit:
- Mutation of GATA3 in human breast tumorsOncogene, 2004
- Prediction of prognosis of estrogen receptor‐positive breast cancer with combination of selected estrogen‐regulated genesCancer Science, 2004
- Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to TamoxifenCancer Research, 2004
- The Impact of Hormone Receptor Status on the Clinical Efficacy of the New-Generation Aromatase Inhibitors: A Review of Data from First-Line Metastatic Disease Trials in Postmenopausal WomenThe Breast Journal, 2004
- Gene Expression Patterns in Ovarian CarcinomasMolecular Biology of the Cell, 2003
- Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reactionBiochemical Pharmacology, 2002
- Hormone receptor status in primary breast cancer—time for a consensus?European Journal of Cancer, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptorInternational Journal of Cancer, 1993
- Hormone Receptor Assays: Clinical Usefulness in the Management of Carcinoma of the BreastCRC Critical Reviews in Clinical Laboratory Sciences, 1988